Rapport talks up $122M IPO to support proof-of-concept epilepsy trials

Rapport Therapeutics is talking up a $122 million IPO, the first in a return to public market interest since an earlier rush this year.

The Third Rock epilepsy biotech is offering 8 million shares, with a range of $16 and $18. Assuming the $17 mid-range price, the offering could net as much as $136 million. The underwriters will have a chance to buy an additional 1.2 million shares.